Resultados de la búsqueda - Portal de Modelos de Datos Médicos (MDM-Portal)

Filtrar resultados de búsqueda
Seleccionar modelos de datos

Modelos de datos seleccionados

Debe iniciar sesión para seleccionar modelos de datos para descargar o realizar un análisis.

199 Resultados de la búsqueda.

Serious Adverse Events Mepolizumab HES NCT00086658 - Serious Adverse Events

- 5/6/17 - 1 formulario, 12 itemgroups, 55 items, 1 idioma

Itemgroups: Serious Adverse Events, Document section, Document section SAE, Document section Demography data, Document section, Document section Causations SAE, Document section Medical Conditions, Document section Risk factors, Document section Concomitant Medications, Document section, Document section, Document section

Study part: .A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Non-Serious Adverse Events Mepolizumab HES NCT00086658 - Non-Serious Adverse Events

- 5/6/17 - 1 formulario, 1 itemgroup, 11 items, 1 idioma

Itemgroup: Non-Serious Adverse Events

Study part: Non-Serious Adverse Events.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Concomitant Medication Mepolizumab HES NCT00086658 - Concomitant Medication

- 5/6/17 - 1 formulario, 1 itemgroup, 11 items, 1 idioma

Itemgroup: Concomitant Medication

Study part: Concomitant Medication.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pharmacogenetic Research Mepolizumab HES NCT00086658 - PGx- Pharmacogenetic Research

- 5/6/17 - 1 formulario, 4 itemgroups, 11 items, 1 idioma

Itemgroups: consent Pharmacogenetic Test, BLOOD SAMPLE COLLECTION, WITHDRAWAL OF CONSENT, BLOOD SAMPLE DESTRUCTION

Study part: PGx- Pharmacogenetic Research.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Mepolizumab HES NCT00086658 - Corticosteroid Medication

- 5/6/17 - 1 formulario, 1 itemgroup, 8 items, 1 idioma

Itemgroup: Medication Corticosteroid

Study part: Corticosteroid Medication.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Investigational Product Discontinuation Mepolizumab HES NCT00086658 - Investigational Product Discontinuation

- 5/6/17 - 1 formulario, 1 itemgroup, 4 items, 1 idioma

Itemgroup: Investigational Product Discontinuation

Study part: Investigational Product Discontinuation.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Study conclusion Mepolizumab HES NCT00086658 - Study conclusion

- 5/6/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma

Itemgroup: STUDY CONCLUSION

Study part: Study conclusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Status of treatment blind Mepolizumab HES NCT00086658 - Status of treatment blind

- 5/6/17 - 1 formulario, 1 itemgroup, 5 items, 1 idioma

Itemgroup: Status of treatment blind

Study part: Status of treatment blind.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Pregnancy Information Study Conclusion Mepolizumab HES NCT00086658 - Pregnancy Information Study Conclusion

- 5/6/17 - 1 formulario, 1 itemgroup, 1 item, 1 idioma

Itemgroup: PREGNANCY INFORMATION

Study part: Pregnancy Information Study Conclusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Eligibility Criteria Day 1 Pre-Infusion Mepolizumab HES NCT00086658 - Eligibility Criteria Day 1 Pre-Infusion

- 4/6/17 - 1 formulario, 3 itemgroups, 21 items, 1 idioma

Itemgroups: Eligibility criteria, Inclusion Criteria, Exclusion Criteria

Study part: Eligibility Criteria Day 1 Pre-Infusion.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Vital Signs Screening Visit Mepolizumab HES NCT00086658 - Vital Signs Screening Visit

- 4/6/17 - 1 formulario, 1 itemgroup, 9 items, 1 idioma

Itemgroup: VITAL SIGNS

Study part: Vital Signs Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

12-Lead ECG Screening Visit Mepolizumab HES NCT00086658 - 12-Lead ECG Screening Visit

- 4/6/17 - 1 formulario, 1 itemgroup, 3 items, 1 idioma

Itemgroup: 12-Lead ECG

Study part: 12-Lead ECG Screening Visit.A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Utilice este formulario para comentarios, preguntas y sugerencias.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.